No randomized clinical trial comparing treatment options for small saphenous vein (SSV) incompetence exists, and there is no clear evidence that this axis behaves the same as the great saphenous vein after treatment. This means that the existing literature base, centered on the treatment of great saphenous vein incompetence cannot simply be extrapolated to inform the management of SSV insufficiency. This trial compares the gold standard of conventional surgery and endovenous laser ablation (EVLA) in the management of SSV incompetence. Methods: Patients with unilateral, primary saphenopopliteal junction incompetence and SSV reflux were randomized equally into parallel groups receiving either surgery or EVLA. Patients were assessed at baseline and weeks 1, 6, 12, and 52. Outcomes included successful abolition of axial reflux on duplex, visual analog pain scores, recovery time, complication rates, Venous Clinical Severity Score, and quality of life profiling. Results: A total of 106 patients were recruited and randomized to surgery (n = 53) or EVLA (n = 53). Abolition of SSV reflux was significantly higher after EVLA (96.2%) than surgery (71.7%) (P < 0.001). Postoperative pain was significantly lower after EVLA (P < 0.05), allowing an earlier return to work and normal function (P < 0.001). Minor sensory disturbance was significantly lower in the EVLA group (7.5%) than in surgery (26.4%) (P = 0.009). Both groups demonstrated similar improvements in Venous Clinical Severity Score and quality of life. Conclusion: EVLA produced the same clinical benefits as conventional surgery but was more effective in addressing the underlying pathophysiology and was associated with less periprocedural morbidity allowing a faster recovery. (Registration number: NCT00841178.)
junction (SPJ) incompetence with associated small saphenous vein (SSV) reflux. [3] [4] [5] Symptomatic small saphenous axis incompetence is significant and can result in a greater disease-specific quality of life (QOL) impairment than incompetence in the GSV axis, when controlling for clinical disease severity. 6 SPJ ligation with or without stripping of SSV is currently the accepted gold standard surgical treatment of SSV axis incompetence. 7 This procedure is generally considered more challenging than groin dissection due to the varied SPJ anatomy and the close proximity to sensory and motor nerves. The risk of complications therefore increases with thorough exploration of the popliteal fossa whereas limited exploration potentiates the risk of recurrence. 8 This technical dilemma was highlighted in a survey of the Vascular Surgeons of Great Britain and Ireland wherein there was lack of consensus on the best surgical technique for SPJ/SSV incompetence. 7 In addition, disappointingly high residual and recurrent varicosities after SPJ ligation provide an impetus for surgeons to consider alternate treatment modalities. 9 Newer minimally invasive endothermal ablation procedures are being increasingly used for SSV reflux, with promising results in case series. [10] [11] [12] [13] Although the advantages of minimally invasive procedures over conventional surgery in the treatment of the GSV are well established in the context of randomized trial and meta-analyses, [14] [15] [16] [17] no such evidence exists in the treatment of the SSV. There is some suggestion that the SSV may behave differently to the GSV after treatment, 6 precluding extrapolation of the current evidence base centered upon GSV management. This study aimed to generate level 1 evidence in the management of SSV reflux by comparing the safety, technical efficacy, and clinical effectiveness of conventional surgery and minimally invasive endovenous laser ablation (EVLA).
METHODS
This nonblinded single center randomized controlled trial, the Hull Endovenous Laser Project 2 (HELP-2), was approved by the local research ethics committee and the institutional research and development departments. Patients presenting to a tertiary referral vascular surgical department with primary symptomatic varicose veins during October 2005 to January 2010 were assessed for suitability to participate in this trial.
The inclusion criteria were primary, symptomatic, unilateral varicose veins, with isolated SPJ incompetence, causing reflux into the SSV. Incompetence on duplex ultrasound (DUS) was defined as retrograde flow of ≥1 second on spectral Doppler after augmentation. The exclusion criteria were reflux in the GSV axis or deep veins on DUS examination, previous treatment of ipsilateral varicose veins, deep venous obstruction, younger than 18 years, pregnancy, impalpable foot pulses, and inability to give informed consent or complete questionnaires during participation in the trial.
Patients were initially seen in a 1-stop varicose veins clinic, where a detailed clinical assessment and DUS examination was un-and performing endovenous procedures 18, 19 Following informed written consent, eligible patients were randomized using sealed, opaque envelopes to receive either surgery or EVLA.
The power calculation was based on the presence of persistent SSV reflux on DUS after surgery (Joint Vascular Research Group study) 20 versus reflux rates post-EVLA (based on unpublished pilot work). Using the χ 2 test with continuity correction, 48 limbs were required per group to detect a statistically significant difference in the proportion of patients with residual reflux at 6 weeks at the 5% level with 80% power. Allowing for a 10% loss to follow-up, 53 patients were required in each group.
Interventions
All patients underwent preoperative DUS marking of the SPJ, SSV, incompetent perforators, and varicose tributaries in the standing position.
All surgical procedures involved formal exploration of the popliteal fossa under general anesthesia, predominantly undertaken as day case procedures. Saphenopopliteal ligation was attempted followed by inversion stripping of the SSV. Where the SSV drained directly into the popliteal vein (PV), the level of ligation of the SSV was flush with the PV. If the SSV joined the gastrocnaemius vein (GV) before the PV, then the level of ligation was at the junction with the GV. If the SSV extended cranially above the SPJ, then this was simply ligated. If there was no SPJ present within the popliteal fossa and the SSV extended cranially terminating in a junction with the deep vein below the midthigh, then it was ligated at that junction. The sural nerve, where seen, was protected during SSV dissection; no other nerves were exposed and retractors were placed with caution. In those limbs where inversion stripping of SSV was not possible, a short proximal segment of SSV (<5 cm) was excised under direct vision.
All EVLA procedures were performed under local tumescent anesthesia in a dedicated clean procedure room within the outpatient department. Ultrasound-guided percutaneous cannulation was performed with the patient in the prone, reverse Trendelenburg position. The site of SSV access was the lowest point of demonstrable reflux above the ankle. A 5 Fr catheter was introduced into the vein using the Seldinger technique, and its tip was accurately positioned under ultrasound guidance at the SPJ to achieve flush occlusion at the same anatomical locations at which the ligations were performed in the open surgery group. The patient was then placed in the Trendelenburg position, and perivenous tumescent local anesthetic (20 mL of 2% lidocaine with 1:200,000 adrenaline and 20 mL of 0.5% levobupivicaine in 1 L of 0.9% saline) infiltrated along the axial vein and tributaries. A bare-tipped 600-nm laser fiber was then introduced via the catheter, and laser energy was delivered using an 810-nm diode laser generator (Diomed/Angiodynamics, Cambridge, United Kingdom) at 14 W power aiming for an energy delivery of 80 to 100 J/cm.
In both groups, stab incisions were made over varicose tributaries, and the veins were avulsed using a kocher's mosquito clip or vein hook. Incompetent perforating veins, when present, were also concomitantly divided and ligated through a 1.0-to 1.5-cm incision. Stab incisions were closed with Steri-stripsTM (3M, St Paul, MN) and cotton wool and Panelast (Lohmann & Rauscher International GmbH & Co. KG, Rengsdorf, DE) elastic adhesive bandage was applied from ankle to midthigh. This was left in situ until the first follow-up at 1 week; it was then changed to a thigh length T.E.D. stocking (Tyco Healthcare, Gosport, United Kingdom), which patients were advised to wear for a further 5 weeks. Postprocedure, both groups were given identical written instructions to mobilize immediately; to return to normal activities, as much as they were able, as soon as they felt comfortable; and to refrain from driving until able to safely perform emergency maneuvers. A week's course of diclofenac 50 mg 3 times a day and paracetamol 1 g 4 times a day was prescribed to all patients, with no associated contraindication to their use, to be taken regularly. Patients judged to be at increased risk of deep vein thrombosis (DVT) (those with a history of DVT or family history of DVT, women taking oral oestrogens, immobility) were given prophylactic dose of low-molecular-weight heparin-dalteparin at 5000 IU/d for 5 days.
Outcomes
Because of the nature of the interventions, it was not possible to blind the investigators or patients to the treatment methods. Patients were assessed at 1, 6, 12, and 52 weeks postprocedure. The primary outcome measure was early technical success, defined as abolition of SSV reflux at 6 weeks postprocedure on DUS assessment.
Secondary Outcomes
Safety was assessed by prospective clinical evaluation, augmented by DUS assessment at each point of follow-up.
Postprocedural pain scores were recorded by the patient in a pain diary, using an unmarked 10-cm visual analog scale (0, no pain; 10, worst imaginable pain) daily for the first week, alongside the requirement for supplementary analgesia, the time taken to return to work and normal activity postprocedure. Patient satisfaction with the cosmetic outcome and with the overall intervention was recorded on 10-cm unmarked visual analog scales (0, completely unsatisfied; 10, completely satisfied) at 12 and 52 weeks.
Objective assessment of the severity of venous disease was performed initially using the clinical grade of the Clinical Etiologic Anatomic Pathophysiologic classification system (from C0, representing no disease, to C6 characterizing active venous ulceration). 21, 22 The Venous Clinical Severity Score (VCSS) (a continuous scale from 0 representing no clinical evidence of venous disease to a maximum of 30) was also used as a dynamic assessment to demonstrate changes in clinical severity over time. The VCSS has been shown to be a valid and responsive measure of the severity of venous disease. [23] [24] [25] Disease-specific QOL was assessed using the Aberdeen Varicose Vein Questionnaire, which measures the QOL impairment directly associated with venous disease. This is scored from 0 (no impact upon QOL) to a theoretical maximum of 100. This popular instrument has also been shown to be reliable, valid, and responsive to measure the specific impact of venous disease on patient's QOL. [26] [27] [28] Generic QOL was assessed using 2 instruments: 36-Item Short Form Health Survey UK version 1 (SF-36 V1) was used to produce a health profile across 8 physical and psychological domains, each scored from 0 (worst possible) to 100 (best possible). The domain profiles include physical function, role limitation due to physical disability (role-physical), bodily pain, general health, vitality, social function, and role limitation due to emotional problems (roleemotional) and mental health. Second, the EuroQol 5D instrument (EQ-5D; EuroQol Group, Rotterdam, The Netherlands) was used to derive a single index valuation, commonly used in the calculation of quality-adjusted life years in economic evaluation. 29, 30 Both these questionnaires have been validated to measure efficacy of venous treatment. [26] [27] [28] [31] [32] [33] [34] samples. Friedman test was used to analyze multiple related samples across the study interval. Categorical data were analyzed using the χ 2 test or the Fisher exact test when necessary.
RESULTS
A total of 767 patients were assessed for eligibility to participate in the trial. One hundred six patients (106 legs) were randomized and received treatment as intended ( Fig. 1) . Baseline demographics were comparable between the 2 groups with the majority being women, predominantly presenting with uncomplicated C2 venous disease ( Table 1) .
Interventions
In the surgery group, the SPJ was identified and flush ligation was possible in 51 (96.2%) legs; however, inversion stripping of the SSV was possible only in 35 (66%) legs. In the remaining 18 patients, complete stripping was not possible due to vein snapping, tortuosity, spasm, or a combination of the above. Because of this, the median (interquartile) length of SSV stripped was only 10 (3-19) cm across the 53 patients in comparison with the EVLA group where the length of SSV ablated was 24.5 (18.3-30.5) cm P < 0.001. In the EVLA group, successful thermal ablation was achieved in all 53 (100%) patients; the mean (SD) energy density delivered was 99.2 (18.6) J/cm. There was no significant difference in the mean (SD) procedure duration for surgery and EVLA: 63.6 (16.6) versus 58.5 (14.8) minutes, respectively (P = 0·111). Unsuitability for day-case general anesthesia necessitated 4 of 53 (7.5%) inpatient treatments in the surgical group in comparison with 1 of 53 (1.8%) in the EVLA group who required overnight stay postprocedure (P = 0.362).
Technical Success
The primary outcome of abolition of SSV reflux on DUS at 6 weeks was significantly higher for 51 (96.2%) patients in the EVLA group than 38 (71.7%) patients in the surgery group (P < 0.001) ( Table 2 ). The relative risk (95% confidence interval) of early success with EVLA compared with surgery was 1·34 (1·11-1·44), giving a risk difference of 0·24 (0·09-0·30). The number needed to treat (NNT) with EVLA rather than surgery to avoid a residual refluxing SSV postprocedure was 4.0 (3.2-10.9). Residual reflux in the surgical group was due to the inability to strip the SSV as previously discussed, whereas in the EVLA group 3 legs developed partial recanalization of the treated segments (having received energy densities of 90, 92, and 99 J/cm, and preprocedural proximal vein diameters of 5.8, 10.7, and 10.4 mm, respectively) between 3 and 12 months.
Complications and Recurrence
Minor complication rates were relatively low in both groups; however, sensory disturbance (predominantly in the sural nerve distribution) was significantly higher in the surgical group at 6-week follow-up-14 (26.4%) patients compared with 4 (7.5%) patients in the EVLA group, P = 0.009. The majority of these cases, however, improved spontaneously leaving persistent sensory disturbance in only 5 (9.4%) surgery patients and 2 (3.7%) EVLA patients, P = 0.434 at 1 year. A single major complication of DVT in the PV was recorded during the 1 week DUS evaluation postsurgery. This otherwise asymptomatic patient was treated with 3 months of oral anticoagulation; the DVT had completely resolved over this time, leaving a patent and competent deep venous system and no clinical evidence of PE.
Clinical recurrence (defined as clinically evident varicose veins at least 3 mm in diameter not present at 1 or 6 weeks but becoming apparent during subsequent follow-up) over the 1-year follow-up period was low in both surgical and EVLA groups: 9 (16.9%) versus 5 (9.4%) legs, respectively; P = 0.390. Patterns of recurrence are listed in Table 3 . Four symptomatic surgical patients required further treatment: Three patients were treated with EVLA of the incompetent residual SSV and concomitant ambulatory phlebectomies; 1 further patient demonstrated disease progression with neoreflux in the previously competent anterior accessory saphenous vein, which was superficial and tortuous and so, was treated by ambulatory phlebectomy under local anesthesia. Ten of 18 patients (55.5%) with intact un-stripped SSV did not develop clinical recurrence; however, at the end of 1-year follow-up, all of these 10 patients continued to have duplex demonstrable SSV reflux. In the EVLA group, 2 patients developed asymptomatic SSV recanalization, having received laser energy density of 90 and 92 J/cm, compared with an overall mean of 99 J/cm; these patients did not want further treatment at this time. Similarly, another patient who demonstrated disease progression with neoreflux in both anterior accessory saphenous vein and midcalf perforator remained asymptomatic and did not consider further treatment. One patient each in the same group developed symptomatic reflux in calf perforators and posterior thigh perforator, which were all ligated under local anesthesia.
Venous Severity Scores
In both groups, there was significant improvement (lower scores) in the VCSS scores over the follow-up period, from a baseline median (IQR) of 3 (2-4) to 0 (0-1) at the end of 12 months (P < 0.001). There was no significant difference between the groups at any time points.
Quality of Life and Patient Satisfaction
Both treatments produced a similar durable improvement in disease-specific QOL scores over the study period (P < 0·001) ( Table 4 ).
Both treatments also demonstrated similar benefits in generic QOL domains and importantly, this culminated in significant quality adjusted life year gains with a significant improvement in index utility scores using the EQ-5D index utility score (P < 0.001) ( Table 4 ).
Patient satisfaction was equally high with either treatment. At 1 year, satisfaction with the overall treatment was a median (IQR) of 9 (8-10) and cosmetic outcome of the treated leg was 8 (7-10) versus 9 (7.2-10) in the surgical and EVLA groups, respectively.
Periprocedural Pain and Return to Normal Functioning
Between days 4 and 7, pain scores were significantly lower in the EVLA group than in the surgical group (Day 4, P = 0.025; Day 5, P = 0.008; Day 6, P = 0.033; Day 7, P = 0.042) (Fig. 2) , despite having no difference in the frequency of analgesia intake. Consequently, patients returned to work and routine activities more quickly after EVLA than after surgery (P < 0·001) ( Fig. 3 ).
DISCUSSION
This study clearly demonstrates that both treatments are safe and effective. They both improve the clinical severity of venous disease as evidenced by the reduction in VCSS scores, thereby resulting in tangible benefit in both generic-and disease-specific QOL. This is the first RCT comparing conventional surgery and minimally invasive endovenous techniques for SSV insufficiency. It was powered to objectively compare the technical outcomes after treatment of SSV incompetence, with the hypothesis that effective abolition of SSV reflux would reduce future recurrence rates. 20 EVLA was clearly found to offer superior early technical success, similar to results from other noncomparative observational studies. [10] [11] [12] [13] [35] [36] [37] With this sample size, recurrence rates were similar at 1 year, but long-term follow-up will establish the fate of those with residual incompetence after failed stripping and the rates of disease progression in a population with successfully treated SSV insufficiency. In this study, the fact that all of the residual, incompetent, unstripped SSVs failed to revert to competence supports the hypothesis that it is the elimination of SSV reflux that is important and that ligation of SPJ alone is insufficient. It is interesting that despite the technical inadequacies of SSV surgery, the clinical recurrence rates were significantly less at 1 year than those observed after successful saphenofemoral junction ligation and stripping. 17 The reason for this is unknown, but this highlights another difference between the management of these 2 distinct clinical patterns. Despite concerns regarding sural nerve injury resulting from SSV stripping, 38 this technique has been shown to decrease recurrence rates after SPJ ligation. 20 As this study was powered to compare the relationship of technical outcomes and recurrence, rather than specifically exploring periprocedural morbidity in depth, SSV stripping was selected as a necessary component in the surgical treatment arm. Despite this, the early technical results of EVLA surpass those of surgery. It is possible that the use of antegrade stripping for those veins that snapped may address this, but this technique was not used in this study.
In common with the early RCTs comparing EVLA and conventional surgery for GSV insufficiency, 15, 39, 40 this study was under-powered for detailed QOL analysis and therefore cannot confirm or refute any true benefit of EVLA over surgery in this area. However, less pain and a faster recovery after EVLA seem promising and have been suggested previously by nonrandomized data. 10, 41 It is possible that the use of tumescent anesthesia before stripping may improve postprocedural pain, immobility, and nerve injury, but this was not used in this study.
Some surgeons are reluctant to use thermal ablation in the management of SSV insufficiency, despite using it in the treatment of GSV and many opt for foam sclerotherapy instead. One reason for this is a perceived difficulty in passing the wire through the SPJ. The treatment protocol in this study aimed for a flush occlusion of the SPJ and in the vast majority of cases within and outside of this trial; a wire can be passed if the junction is a significant source of reflux. Sometimes, a hydrophilic wire can help with a difficult junction, in conjunction with a little rotational torque. In cases in which the true source of reflux is a cranial extension of the SSV or Giacomini vein, the wire often passes preferentially into this vein from the SSV rather than into the deep system. In this case, ablation of the refluxing segment (in some cases as far as the groin) can be performed. Ablating past the SPJ rather than up to it typically leaves either an occluded SPJ or a competent junction receiving flow from the GVs. If the GVs are incompetent preprocedure, however, it is worth initially passing a wire separately through the SPJ and if required a further wire through the cranial extension or Giacomini vein. A further anxiety regarding SSV thermoablation rests with the potential for sural nerve damage; however, it seems, as noted with the GSV, EVLA results in less damage to the accompanying nerve than stripping. This is due to the use of tumescent anesthesia during EVLA and the rates of injury after stripping may be reduced by tumescent use also (although this is not in common practice). As this study is not powered for QOL analysis, the morbidity of the increased early neuropathy rate in the surgical group is unclear.
One of the limitations of this study is that the patients, surgeons, and assessors could not be blinded to the technique used due to the nature of these interventions. Risk of observer bias was, however, reduced as much as possible by recording outcomes (both primary and secondary) with objective, validated instruments, and standardized protocols employed by assessors with relevant qualifications and experience. The QOL outcomes were also independently reported by patients, and the use of both disease-specific and generic instruments provided a valid and reliable strategy to assess patientreported health states after treatment of their venous disease. 27, 42 Any new treatment of varicose veins requires long-term followup to determine recurrence rates, and hence further follow-up will be undertaken in this trial. Recanalization has been reported after EVLA of SSV 11, 13, 35 and may compromise long-term outcomes; a large observational series of 229 SSV EVLAs found a recanalization rate of 1.3% at 2 years, 43 whereas prospective data from this RCT indicates an early rate of 5.6% (3 patients), although it would be inequitable to compare results between studies using different wavelengths and energy densities. In this trial, 1 patient developed full-length SSV recanalization due to neoreflux from a previously competent Giacomini vein whereas the other 2 developed junctional incompetence with reflux into proximal SSV segments, all 3 having been treated above the 810-nm energy density threshold of 60 J/cm. 44 These may be related to the diameter rather than the energy density alone, both of which have been implicated with increased occurrence of recanalization. 11, 13, 43 In summary, this RCT suggests equivalent improvements in clinical severity and at least noninferiority of EVLA compared with conventional surgery in the treatment of SSV incompetence. The immediate postoperative benefits and short-term technical outcomes of EVLA would support the future consideration of this procedure as the standard treatment of small saphenous insufficiency, provided the long-term results are no worse than following surgery.
